Psychiatry and Neurology, Neurology · Tulsa, OK
NPI
1447447487
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
6
Medicare group memberships
Hospitals
5
Hospital affiliations
6565 S Yale Ave Ste 209
Tulsa, OK, 74136
Phone (918) 488-0990
Groups this clinician bills Medicare through
Medicare paid, 2024
$60K
971 services
Medicare patients, 2024
361
Average age 67
Drug cost, 2024
$1.8M
3,870 prescriptions
Company payments, 2025
$3,005
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeremy Salas was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 218 times for 134 patients. In total Jeremy Salas billed 971 services in 21 codes, and Medicare paid $60K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-11-04.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 218 | 134 | $10.65 | $2,322 |
| 95886 Electrical Nerve Conductivity | Office | 207 | 127 | $64.46 | $13K |
| 99214 Office E&M - Established | Office | 179 | 92 | $76.87 | $14K |
| 99213 Office E&M - Established | Office | 68 | 58 | $46.50 | $3,162 |
| 95910 Electrical Nerve Conductivity | Office | 37 | 37 | $124.66 | $4,613 |
| 95911 Electrical Nerve Conductivity | Office | 37 | 37 | $153.67 | $5,686 |
| 95970 Electrical Nerve Conductivity | Office | 29 | 13 | $12.02 | $349 |
| 95816 Neurologic | Facility | 27 | 27 | $38.62 | $1,043 |
| 95909 Electrical Nerve Conductivity | Office | 24 | 24 | $96.39 | $2,313 |
| 95720 Neurologic | Facility | 21 | 13 | $152.16 | $3,195 |
| 99205 Office E&M - New | Office | 21 | 21 | $149.39 | $3,137 |
| 95819 Neurologic | Facility | 21 | 20 | $39.47 | $829 |
| 95816 Neurologic | Office | 16 | 16 | $36.45 | $583 |
| 95912 Electrical Nerve Conductivity | Office | 12 | 12 | $171.22 | $2,055 |
| 95908 Electrical Nerve Conductivity | Office | 11 | 11 | $76.46 | $841 |
By year: 2022 $67K for 882 services; 2023 $55K for 734 services; 2024 $60K for 971 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jeremy Salas prescribed most often to Medicare patients was Levetiracetam, with 621 prescriptions and refills. In total Jeremy Salas wrote 3,870 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 621 | 889 | 96 | $17K |
| Lamotrigine Generic | 481 | 684 | 62 | $6,513 |
| Lacosamide Generic | 458 | 494 | 54 | $46K |
| Topiramate Generic | 218 | 280 | 29 | $2,232 |
| Clobazam Generic | 165 | 174 | 18 | $13K |
| Clonazepam Generic | 147 | 158 | 17 | $2,749 |
| Xcopri Cenobamate | 127 | 135 | 18 | $206K |
| Oxcarbazepine Generic | 120 | 195 | 23 | $8,779 |
| Phenytoin Sodium Extended Generic | 97 | 127 | 11 | $1,976 |
| Briviact Brivaracetam | 74 | 75 | Under 11 | $109K |
| Gabapentin Generic | 73 | 87 | Under 11 | $1,475 |
| Divalproex Sodium Generic | 66 | 106 | 11 | $1,735 |
| Emgality Pen Galcanezumab-Gnlm | 60 | 65 | Under 11 | $48K |
| Aptiom Eslicarbazepine Acetate | 58 | 58 | Under 11 | $129K |
| Carbamazepine Generic | 53 | 67 | Under 11 | $2,975 |
Brand drugs: 720 claims; generic drugs: 3,112 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeremy Salas $3,005 ($3,005 in general payments such as food, travel and fees) from 22 companies. The largest payer was TG Therapeutics, Inc. with $413.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.